Intranasal vaccine Coroflu being developed

A unique intranasal vaccine, Coroflu, is being developed to help with the fight against the COVID-19 pandemic.

About the Vaccine

Coroflu vaccine is being developed by Bharat Biotech in an international collaboration with University of Wisconsin. The human clinical trials of the vaccine will be conducted in the fall of 2020. About 300 million doses are to be produced.

Intranasal Vaccine

Intranasal vaccines are vaccines that are administered through the nose to the mucosal layer. Though it has certain disadvantages like less efficient uptake and fast clearance, it also has certain advantages of being non-invasive, higher patient compliance due to its needle-less administration method, etc.

H2N2 Virus

The Coroflu is based on the influenza vaccine. It will also provide immunity against the H2N2 viral strain that causes seasonal influenza. The H2N2 is a subtype of the Influenza A virus. The Asian Flu is caused by the H2N2 virus. The virus is suspected to be the cause of the 1889 pandemic.